Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Enzalutamide (Primary) ; Everolimus (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 05 Jan 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
- 05 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.